| HS Code | 856565 |
| Product Name | Pill Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Product Category | Active Pharmaceutical Ingredient (API) |
| Grade | Veterinary Grade |
| Target Species | Livestock, poultry, companion animals, and other veterinary species |
| Available Dosage Forms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Active Ingredient Type | Veterinary-grade pharmacological compound for medicinal formulations |
| Quality Standard | Complies with veterinary pharmacopoeial standards such as USP-Vet, Ph. Eur., or equivalent |
| Appearance | White to off-white crystalline or amorphous powder, depending on the specific API |
| Solubility | Formulated for compatibility with aqueous or lipid-based pharmaceutical carriers |
| Storage Conditions | Store in tightly sealed, light-resistant containers in a cool, dry, and well-ventilated area |
| Shelf Life | Typically 24 to 60 months from date of manufacture under recommended storage conditions |
| Packaging | Sealed pharmaceutical-grade multi-layer bags, drums, or containers |
| Usage Classification | For veterinary compounding and pharmaceutical manufacturing only |
As an accredited Pill Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Pill Veterinary Grade API (for tablets, injections, etc.) is packaged as 25 kg in sealed multi-layer bags inside tamper-evident fiber drums. |
| Container Loading (20′ FCL) | A 20′ FCL is loaded with sealed, palletized drums/cartons of veterinary API; secured, protected from moisture/contamination, with proper labelling and documentation. |
| Shipping | Shipping of veterinary-grade API requires strict compliance with international regulations. Products are packed in sealed, moisture-proof containers with clear labeling. Temperature-controlled transport and secure documentation ensure stability, purity, and traceability. Hazardous material protocols apply. We ensure timely delivery worldwide while maintaining product integrity throughout the supply chain. |
| Storage | Store in a tightly sealed, labeled container in a cool, dry, well-ventilated area, away from direct sunlight, moisture, and heat. Maintain recommended temperature range and protect from incompatible materials. Follow manufacturer’s guidelines; ensure area is secure and accessible only to authorized personnel. Avoid contamination; use appropriate handling precautions. |
| Shelf Life | Shelf life: 24 months from manufacture when stored unopened in original container in a cool, dry place. |
Before direct compression is attempted with Pill Veterinary Grade API, the particle-size distribution and bulk density of the active lot must be reconciled with the fill weight and the tooling dimensions. Micronized material with a size fraction above 50% below 75 µm may generate segregation in a low-shear tumbling blender unless the formulation includes a carrier with comparable surface roughness and true density. Direct compression is preferred only when the active material has a Hausner ratio below 1.35 and a flow function coefficient greater than 4; otherwise roller compaction or wet granulation preceded by slugging becomes the rate-determining unit operation. In a standard pilot-scale run, the active mass is pre-blended with microcrystalline cellulose and croscarmellose sodium in a bin blender at 10–25 rpm for 10–20 min, after which magnesium stearate is added and blended for 3–5 min because over-lubrication above 1.0% w/w can reduce tablet tensile strength by more than 50% while delaying dissolution of poorly soluble actives. In-process blend uniformity is tested per 21 CFR 211.110 with acceptance limits of 90.0–110.0% label claim and relative standard deviation below 5.0%. Compression is performed on a rotary tablet press with 8–16 stations, 20–60 rpm turret speed, precompression force 3–8 kN, and main compression force 8–25 kN, adjusted to produce hardness in the range of 60–120 N and friability less than 1.0% per USP <1216> / Ph. Eur. 2.9.7. Critical tablet quality attributes under USP <905> and Ph. Eur. 2.9.40 use the acceptance value approach; failing blends cannot be recovered by post-compression sorting because API segregation occurs within the hopper, not at the die. Dissolution testing is conducted using USP <711> apparatus II with paddle speed 50–75 rpm and a medium selected from the species-specific gastrointestinal compartment. Terminal finished tablets may be scored for oral administration to companion animals or food-producing animals within the approved withdrawal period.
For sterile veterinary injections, the decision between terminal moist heat sterilization and aseptic filtration is driven by the thermal degradation threshold of the active moiety in a defined pH and buffer system. Preformulation forced degradation is conducted at 50–70°C and 75% RH per VICH GL3 before a sterilization cycle is fixed. If the solution remains within 95.0–105.0% of initial potency after an F0 of 15 min at 121°C, terminal sterilization in a water cascade autoclave is selected because it provides a sterility assurance level below 1 × 10−6 per Ph. Eur. 5.1.1. For heat-labile formulations, aseptic processing is required; the solution is filtered through a 0.22 µm membrane, and filter integrity is verified by bubble point or diffusive flow before and after filling per 21 CFR 211.84. Aseptic filling occurs in an ISO 14644-1:2015 Grade A zone with Grade B background, using closed restricted-access barrier systems or isolators with continuous viable and non-viable particle monitoring. Tonicity is adjusted with sodium chloride or dextrose to 270–330 mOsm/kg, and pH is controlled within the buffering capacity of phosphate or citrate species. Endotoxin limits are established by product-, route-, and species-specific risk assessment under USP <85> / Ph. Eur. 2.6.14; no universal limit applies across all veterinary parenterals. For oxidation-sensitive APIs, headspace nitrogen sparging to residual oxygen below 2.0% v/v and Type I borosilicate glass vials with coated stoppers are used to prevent oxidative colour change and assay loss. Terminal products include single-dose and multi-dose injectable solutions or suspensions for cattle, swine, and companion animals, with all components terminally inspected for particulate matter per USP <788>.
Medicated premix manufacture starts with a stepwise dilution of Pill Veterinary Grade API into a carrier system such as calcium carbonate, rice hulls, or corn cob, selected for particle size, oil absorption, and electrostatic charge. The first pass often uses a ribbon blender or paddle mixer at 20–40 rpm with fill volume kept between 60–75% of working capacity; the active premix is screened through a 600–1000 µm mesh and then diluted geometrically to avoid drug-rich zones that would produce superpotent feed aliquots. Equipment cleanout and carryover validation are governed by 21 CFR 225.65 and 21 CFR 558.6; sampling must demonstrate that residual drug is below the level that would cause a toxic or violative residue in the following non-medicated feed production run. Production sequencing, dust extraction, and flushing with a non-medicated carrier are common controls, and the cleanout sequence is validated with a tracer or representative active. Because electrostatic adhesion in low-humidity plants below 40% RH can increase carryover onto polyethylene and stainless steel surfaces, moisture conditioning and bonded earth grounding of mixers are part of the installation qualification. The terminal product is a homogeneous Type A medicated article or a Type B/C feed for species-specific inclusion rates, with every manufactured lot inspected for moisture, bulk density, and drug content before release.
In low-dose oral powder manufacture, the greatest technical risk is not chemical degradation but mass-flow interruption at the sachet filling head. Pill Veterinary Grade API that is milled below 50 µm for rapid dissolution in drinking water will often exhibit a Hausner ratio above 1.40 and a flow function coefficient below 3, making direct filling impractical. The material is therefore granulated in a high-shear mixer or fluid-bed granulator with a binder such as povidone or hydroxypropyl methylcellulose at 5–15% w/w solids, dried to a loss on drying below 2.0% w/w, and sieved to a D50 of 150–350 µm. The granulate is filled on vertical form-fill-seal equipment with weigh cells or volumetric auger fillers; fill weight variability is kept below 2.0% RSD, and seal integrity is tested per ASTM F2096-11. Individual sachets are pouched in low water vapour transmission rate laminates if the API is hygroscopic. Terminal product is an oral powder for administration via feed or drinking water, often at low inclusion rates in poultry or swine.
| Finished dosage form | Potency/uniformity | Physical integrity/disintegration | Microbial/sterility | Primary regulatory frame |
|---|---|---|---|---|
| Tablet | USP <905>, Ph. Eur. 2.9.40 | USP <1216>, USP <701> | USP <61>/<62> | 21 CFR 211.110 |
| Injection | USP <905> | Particulate matter USP <788> | USP <71>, USP <85> | 21 CFR 211.113, ISO 14644-1:2015 |
| Capsule | USP <905>, Ph. Eur. 2.9.40 | USP <701>, USP <711> | USP <61>/<62> | 21 CFR 211.110 |
| Oral powder/granule | USP <905> | Fill weight RSD ≤2.0%, ASTM F2096-11 | USP <61>/<62> | 21 CFR 211.110 |
| Premix | Homogeneity under 21 CFR 225.65 | Carryover validation 21 CFR 225.65 | Salmonella and Enterobacteriaceae control | 21 CFR 558.6 |
| Oral solution | Assay and pH stability | Fill volume and package integrity | USP <51>, Ph. Eur. 5.1.3 | USP <1664> |
Low-dose capsule compounding requires that the active content per unit be achieved without the segregation that develops when free-falling powder from a hopper enters the die bore at inconsistent rates. For a dosator-type capsule filler, the powder plug is formed at a compression ratio between 3:1 and 5:1; for a tamping pin machine, station-to-station consistency is maintained only when the blend has a Hausner ratio below 1.25, a Carr index below 20%, and an angle of repose below 35°. If Pill Veterinary Grade API itself is needle-shaped or electrostatic, geometric dilution through a 600 µm sieve into lactose monohydrate and microcrystalline cellulose is used before adding colloidal silicon dioxide at 0.5–1.0% w/w and magnesium stearate at 0.25–0.75% w/w. Over-lubrication is monitored because hydrophobic films on the active surface can delay disintegration beyond 30 min under USP <701> / Ph. Eur. 2.9.1. Finished capsules are tested for weight variation and content uniformity using USP <905>, and dissolution uses USP <711> with a species-relevant medium. Hard gelatin capsules are used for low-moisture formulations, while HPMC capsules are specified where aldehyde crosslinking or moisture uptake above 5.0% w/w is a concern. Terminal product is an oral capsule for companion animals or food-producing species.
At water activity above 0.85, the primary degradation route for a dissolved veterinary API is pH-dependent hydrolysis, and rate profiling must be completed before a preservative system is chosen. Oral solutions and drenches containing Pill Veterinary Grade API are prepared in purified water, often with propylene glycol, glycerol, or polyethylene glycol as cosolvent for slightly soluble actives. Forced degradation at 40°C / 75% RH and at 60°C over short intervals is required to establish the pH of maximum stability; buffers such as citrate or phosphate are then incorporated at 10–50 mM to resist pH drift during shelf storage. Antimicrobial preservation is developed under Ph. Eur. 5.1.3 / USP <51>, with preservative type and concentration matched to the species of administration; benzyl alcohol and parabens are not interchangeable across all veterinary species, and cat-specific restrictions apply. The solution is filled by volumetric or gravimetric filling into Type III glass or high-density polyethylene bottles; if plastic packaging is used, leachables are assessed under USP <1664>. Light-protective packaging is added when photodegradation results in more than 5% assay loss during VICH confirmatory studies. Terminal product is an oral drench or drinking water solution with label-specific dilution volumes and withdrawal periods for food-producing animals.
Competitive Pill Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Product designation Pill Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions identifies a route-differentiated veterinary active pharmaceutical ingredient grade rather than a single uniform powder. Model identifiers PVG-API-O, PVG-API-I, and PVG-API-P correspond to oral solid-dose, injectable-ready, and medicated-feed/premix streams. The materials are produced by crystallization, vacuum drying, size reduction, classification, and blending; injectable-ready lots are packaged in LDPE-lined aluminium foil bags under nitrogen after a headspace oxygen check below 2.0%. Release includes assay by HPLC, related substances, residual solvents, elemental impurities, particle-size distribution, and microbiological quality. This grade is intended for further processing into tablets, capsules, injections, powders, granules, premixes, and solutions, and it differs from technical-grade or feed-additive material by its pharmacopoeial test burden, documentation package, and route-specific control of particulate and endotoxin burden.
The three model identifiers are released against different quality profiles because the downstream dosage-form risk is not identical. Oral tablet and capsule manufacture requires control of particle size and related substances, while injectable manufacture requires a low bioburden and a defined bacterial endotoxin limit. The following matrix summarizes release benchmarks for a representative multi-source veterinary API. Limits are product-specific for a particular molecular entity, and a marketing authorization holder may tighten related-substance specifications when a food-producing species has a lower residue limit.
| Quality attribute | PVG-API-O oral solid-dose | PVG-API-I injectable-ready | PVG-API-P premix | Test method / standard |
|---|---|---|---|---|
| Assay, dried basis | 98.0–102.0% w/w | 98.0–102.0% w/w | 98.0–102.0% w/w | Ph. Eur. 2.2.29 |
| Loss on drying | ≤ 0.5% | ≤ 0.5% | ≤ 1.0% | Ph. Eur. 2.2.32 |
| Related substances | single unknown ≤ 0.10%; total ≤ 1.0% | single unknown ≤ 0.10%; total ≤ 1.0% | single unknown ≤ 0.20%; total ≤ 2.0% | Ph. Eur. 2.2.29 |
| Particle size | D90 ≤ 150 µm | D90 ≤ 75 µm | D10/D50/D90 report only | Ph. Eur. 2.9.31 |
| Bacterial endotoxins | Not specified | ≤ 0.5 EU/mg | Not specified | Ph. Eur. 2.6.14 |
| Microbial enumeration | TAMC ≤ 10³ CFU/g; TYMC ≤ 10² CFU/g | TAMC ≤ 10² CFU/g; TYMC ≤ 10¹ CFU/g | TAMC ≤ 10⁴ CFU/g; TYMC ≤ 10² CFU/g | Ph. Eur. 2.6.12 / 2.6.13 |
| Residual solvents | Class 1 prohibited; Class 2 within ICH Q3C Option 1 and VICH GL18; Class 3 limited by GMP | ICH Q3C / VICH GL18 | ||
The injectable-ready model is not sterilized at API release. It is controlled to a pre-sterilization bioburden that is compatible with a downstream sterile filtration or terminal steam sterilization load at the finished-drug level.
Particle-size distribution is not a cosmetic parameter for the oral solid-dose stream. In direct-compression tablet formulations, lot-to-lot D90 shifts above 150 µm can produce content-uniformity failures under Ph. Eur. 2.9.40, particularly when the API represents less than 2.0% w/w of the tablet core. Milling through a conical comill fitted with a 0.5 mm rasping screen and round impeller operating at 6000 rpm typically achieves the PVG-API-O target, but overmilling below a D50 of 10 µm can increase electrostatic charging and reduce flow. At production scale, a 600 L bin blender operating at 8 rpm and 60% fill volume provides acceptable blend uniformity only when the API Hausner ratio remains between 1.2 and 1.4. When the API is pre-blended at 0.5% w/w with microcrystalline cellulose before the main blending step, segregation in a direct-compression run can be reduced; however, published data for this specific configuration is limited, and a linear blender trial is required before routine use.
Polymorph identity is monitored by X-ray powder diffraction and differential scanning calorimetry. If the API is hydrate-sensitive, a polymorphic transition during drying above 50°C can change dissolution in capsule formulations. For such substances, the drying step is validated with a maximum product temperature of 45°C. The premix stream is not milled to the same D90 as the oral stream because a fine powder can segregate from feed carriers. Instead, the PVG-API-P particle-size distribution is reported as D10/D50/D90 by laser diffraction, and the formulator confirms that the chosen sieve fraction remains homogeneous in the intended feed carrier.
Selection of the injectable-ready stream does not make the final injection sterile. Terminal steam sterilization at 121.1°C with an F0 ≥ 8 min remains a drug-product operation. The API must withstand a forced degradation hold at 121°C for 30 min in the intended vehicle; if related substances increase by more than 1.0% absolute, terminal sterilization is not justified and aseptic filtration becomes the method of choice. In aseptic processing, the bulk solution is clarified through a 0.45 µm filter and then passed through a sterilizing-grade 0.22 µm PVDF filter at a differential pressure below 2.1 bar. Higher differential pressure can induce particulate shedding from polymeric membranes and can mask a filter-integrity failure. Filter integrity is tested after filtration by bubble point or diffusive flow against the filter manufacturer’s minimum acceptance value.
The PVG-API-I limit of ≤ 0.5 EU/mg is necessary but not sufficient. Depyrogenation of vials, stoppers, and process contact surfaces must be performed separately, and the final product endotoxin limit is derived from the maximum veterinary dose and target species body weight. If an API has a melting point below 170°C, dry-heat depyrogenation of the API itself is not feasible; instead, endotoxin control is moved upstream into crystallization, water quality, and packaging components. This operational boundary prevents a false assumption that low API endotoxin alone can compensate for non-depyrogenated packaging.
Premix and granulated products containing 0.1–1.0% w/w API can segregate if the API has a D50 below 10 µm and the carrier has a D50 above 300 µm. In a 500 kg horizontal ribbon mixer, geometric dilution is performed in at least three stages, beginning with a 1:5 API-to-carrier premix and ending with a total mix time of 12 min at a rotor speed of 20 rpm. Mixing beyond 20 min can increase electrostatic dusting and reduce discharge potency. For low-dose tablets, high-shear wet granulation with an impeller speed of 150 rpm and chopper speed of 1500 rpm, followed by fluid-bed drying at an inlet air temperature of 60°C, improves distribution but can cause API particle dissolution and re-precipitation on the granule surface if the binder solvent has high API solubility. This recrystallization is controlled by binder addition rate and by an end-of-spray mass balance check. Blend uniformity acceptance for tablets is typically set at an RSD of ≤ 5.0% using HPLC assay after sampling from defined blender locations.
Each lot is released after quality assurance review of the master batch record, packaging record, and certificate of analysis. A batch record includes lot numbers for crystallization, drying, milling, blending, and packaging; in-process checks include particle-size analysis after milling, blend homogeneity after blending, and moisture after drying. Process validation is performed on 3 consecutive batches at the intended commercial scale. The documentation package for food-producing species includes an EU maximum residue limit reference where applicable under Regulation (EC) No 470/2009, although the API manufacturer does not establish the withdrawal period; the marketing authorization holder derives that from the formulated product, dosage, and target species.
Compared with feed-additive and technical-grade material, the veterinary API grade carries operational differences that are visible at the pharmacy and on the production line. A technical-grade batch may be released with an assay of ≥ 95.0% and no endotoxin control; a PVG-API-I batch is released at 98.0–102.0% with a bacterial endotoxin limit of ≤ 0.5 EU/mg and a residual solvent report aligned to VICH GL18. The oral solid-dose stream is differentiated by particle-size specification and polymorph identity, not only by chemical purity. Feed-additive grade frequently lacks a documented stability program; this product is placed in a stability protocol following VICH GL2 with storage at 25°C / 60% RH and 40°C / 75% RH for zone IVb assignments. Documentation includes batch manufacturing records, change-control history, and analytical method validation per VICH GL1.
| Feature | Pill Veterinary Grade API | Technical grade | Feed-additive grade |
|---|---|---|---|
| GMP status | EU GMP Part II / 21 CFR 210-211 | Not GMP | Feed hygiene only |
| Assay release | 98.0–102.0% w/w | ≥ 95.0% w/w | ≥ 90.0% w/w typical |
| Endotoxin control | ≤ 0.5 EU/mg for PVG-API-I | Not tested | Not tested |
| Residual solvents | VICH GL18 / ICH Q3C | Limited | Not controlled |
| Particle-size release | D10/D50/D90 by laser diffraction | Report only | Sieve only |
| Stability | VICH GL2 protocol | None | None |
The comparison is not merely regulatory. A feed-additive grade with uncontrolled particle size may pass a chemical assay but fail oral tablet content uniformity because the D90 exceeds the direct-compression limit. A technical-grade lot with acceptable purity may still be unsuitable for injection because it lacks endotoxin and bioburden control. The Pill Veterinary Grade API is therefore specified according to the intended finished dosage form rather than as a single acceptable purity range.
Residual solvent failures in veterinary API batches are most commonly caused by insufficient vacuum drying after a water-isopropanol recrystallization. A rotary vacuum dryer with a jacket temperature of 50°C and a final pressure of 20 mbar can reduce isopropanol below the ICH Q3C Class 3 limit of 0.5%, but the drying endpoint must be confirmed by headspace gas chromatography rather than by loss on drying alone. For moisture-sensitive APIs, the PVG-API-I stream is filled into LDPE-lined aluminium foil bags after nitrogen purging. If the API is hygroscopic and ambient relative humidity exceeds 60% RH, dispensing should occur in a dry room with a dew point below −40°C. Failure to control water uptake can shift polymorph form, alter dissolution behavior, and decrease flowability.
Tablets and capsules use PVG-API-O after geometric pre-blending at 0.5–5.0% w/w, followed by direct compression or wet granulation. Injections use PVG-API-I after dissolution in Water for Injection and pH adjustment within the stability range of the molecule. Powders and premixes use PVG-API-P in stepwise dilution with lactose monohydrate, corn starch, or feed-grade calcium carbonate. Granules are produced by high-shear wet granulation or fluid-bed top-spray granulation. Oral solutions are prepared by dissolving the API in purified water with an antimicrobial preservative system for multi-dose presentations. The injectable-ready stream is not intended for direct use without a terminal sterilizing or aseptic filtration step at the finished-drug stage.
